Articles

FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer

The FDA has granted Priority Review to Roche's investigational oral SERD, giredestrant, for the adjuvant treatment of ER+/HER2- breast cancer. This decision is based on Phase III data demonstrating a significant reduction in recurrence risk.

FDA's Shifting Tides: Navigating Clinical Trials Amidst Regulatory Uncertainty

The FDA is implementing a modern approach to real-time clinical trials (RTCT), allowing scientists to monitor safety signals and endpoints as trials progress. This initiative follows a period where the agency halted an average of 664 experimental drug trials annually from 2017-2021, highlighting a complex regulatory environment.

FDA Approves Cavhanza Nilotinib ODT

The FDA approved Cavhanza, an orally disintegrating tablet form of nilotinib from Cycle Pharmaceuticals, on June 2, 2026 for adults with Philadelphia chromosome-positive chronic myeloid leukemia. The formulation targets flexible dosing with meals and concomitant acid-reducing agents without timing restrictions.

Tenaya TN-201 MyPEAK-1 Interim HCM Data

Tenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an AAV9 MYBPC3 gene therapy for hypertrophic cardiomyopathy, on June 3, 2026. All six evaluable patients showed hypertrophy improvements; five reached NYHA Class I. The company also said EMA granted PRIME designation for TN-201.

Biosimilars Drive Significant Reductions in Specialty Drug Spending

Biosimilars are poised to significantly reduce specialty drug expenditures, with projections indicating potential savings of up to 20%. This analysis explores the market impact, patient cost benefits, and strategic implications for the pharmaceutical industry.

ALX Oncology to Present at 2026 Jefferies Global Healthcare Conference, Highlighting Oncology Pipeline

ALX Oncology is set to present its oncology pipeline at the 2026 Jefferies Global Healthcare Conference in New York. The presentation, scheduled for June 3rd, will feature a fireside chat format and will be webcast live.

Legend Biotech's In Vivo CAR-T Data Sparks Stock Surge: A Catalyst Tracking Analysis

Legend Biotech's stock experienced a significant surge following the release of initial in vivo CAR-T cell therapy data. This development signals a potential shift in the CAR-T landscape, with implications for manufacturing, accessibility, and competitive dynamics.

Advancing Bladder Cancer Care Through Education and Awareness

Bladder Cancer Awareness Month highlights ongoing challenges and progress in the field. Educational initiatives are crucial for optimizing treatment and improving patient outcomes.

Fulcrum Explores Sale Amid FDA Setback for Sickle Cell Drug

Fulcrum Therapeutics is reportedly exploring strategic alternatives, including a potential sale, after the FDA raised concerns about its lead sickle cell drug, pociredir. This move follows similar market withdrawals for other sickle cell treatments.

EU Publishes Roadmap to Reduce Animal Testing: Implications for Pharma

The European Commission has released a roadmap aimed at phasing out animal testing for chemical safety assessments. This initiative signals a significant shift in regulatory expectations and presents both challenges and opportunities for the pharmaceutical industry.

ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology

ASCO ‘26 showcased significant advancements in oncology, particularly the growing role of bispecific antibodies and antibody-drug conjugates (ADCs). The conference also highlighted a potential 'RAS' revolution and a notable step change in the treatment of prostate cancer.

Celcuity's Gedatolisib Trial Misses Expectations, Highlighting PIK3CA Inhibitor Challenges

Celcuity's Phase 3 VIKTORIA-1 trial for gedatolisib in PIK3CA-mutated breast cancer did not meet 'lofty' expectations, prompting a re-evaluation of PIK3CA inhibitor development. This analysis examines the trial outcomes, competitive landscape, and strategic implications for pharmaceutical teams.

Sun Pharma and Organon File HSR, Awaiting Antitrust Clearance

Sun Pharmaceuticals and Organon & Co. have submitted their Hart-Scott-Rodino premerger notification, with the antitrust waiting period scheduled to expire on June 22. This filing marks a significant step in their potential transaction.

This Week’s Biopharma News: New Approvals, Appeals, and AI

This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.

Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds

A recent Cleveland Clinic study confirms that tissue-derived tumor mutation burden (tTMB) is a more reliable predictor of immunotherapy response compared to blood-based TMB (bTMB). This finding serves as a cautionary note for physicians considering liquid biopsy results alone for treatment decisions.

Celcuity's Gedatolisib: Navigating the Path to Broad FDA Approval in Breast Cancer

Celcuity has announced positive topline data from its Phase 3 VIKTORIA-1 trial for gedatolisib in breast cancer, positioning the company for a broad FDA filing. This development marks a significant catalyst for the company and the broader oncology landscape.

FDA Delays Decision on AstraZeneca's Camizestrant Following Negative Adcomm Vote

The FDA has extended its review period for AstraZeneca's oral SERD drug, camizestrant, following a negative recommendation from an advisory committee. The delay stems from the regulator's need to review additional data requested after the panel raised concerns about the Phase 3 SERENA-6 trial's design and the lack of survival data.

Navigating FDA's Clinical Trial Transparency Enforcement: A Practical Guide for Sponsors and Sites Post-April 2026

Following FDA's April 2026 reminders, this guide details the critical aspects of clinical trial transparency enforcement for sponsors and research sites. It outlines the regulatory landscape, potential consequences of non-compliance, and actionable strategies to ensure adherence to evolving transparency mandates.

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

Kazia Therapeutics has announced the appointment of James Levine as its new Chief Financial Officer, effective June 1, 2026. Levine brings over two decades of experience in investment banking and financial leadership within the biotech sector.

FDA Declines Cingulate's ADHD Drug CTx-1301 Over Manufacturing Concerns

The U.S. Food and Drug Administration (FDA) has declined to approve Cingulate's attention deficit hyperactivity disorder (ADHD) treatment, CTx-1301, due to manufacturing-related concerns. While the drug's safety and effectiveness were not questioned, the Complete Response Letter (CRL) signifies a delay in the company's market entry.